Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer
- PMID: 28002555
- PMCID: PMC5531287
- DOI: 10.1001/jamasurg.2016.4749
Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer
Abstract
Importance: Contralateral prophylactic mastectomy (CPM) use is increasing among women with unilateral breast cancer, but little is known about treatment decision making or physician interactions in diverse patient populations.
Objective: To evaluate patient motivations, knowledge, and decisions, as well as the impact of surgeon recommendations, in a large, diverse sample of patients who underwent recent treatment for breast cancer.
Design, setting, and participants: A survey was sent to 3631 women with newly diagnosed, unilateral stage 0, I, or II breast cancer between July 2013 and September 2014. Women were identified through the population-based Surveillance Epidemiology and End Results registries of Los Angeles County and Georgia. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). Associations between CPM receipt and surgeon recommendations were also evaluated. All statistical models and summary estimates were weighted to be representative of the target population.
Main outcomes and measures: Receipt of CPM was the primary dependent variable for analysis and was measured by a woman's self-report of her treatment.
Results: Of the 3631 women selected to receive the survey, 2578 (71.0%) responded and 2402 of these respondents who did not have bilateral disease and for whom surgery type was known constituted the final analytic sample. The mean (SD) age was 61.8 (12) years at the time of the survey. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Ultimately, 1466 women (61.6%) received BCS, 508 (21.2%) underwent UM, and 428 (17.3%) received CPM. On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). Among 1569 patients (65.5%) without high genetic risk or an identified mutation, 598 (39.3%) reported a surgeon recommendation against CPM, of whom only 12 (1.9%) underwent CPM, but among the 746 (46.8%) of these women who received no recommendation for or against CPM from a surgeon, 148 (19.0%) underwent CPM.
Conclusions and relevance: Many patients consider CPM, but knowledge about the procedure is low and discussions with surgeons appear to be incomplete. Contralateral prophylactic mastectomy use is substantial among patients without clinical indications but is low when patients report that their surgeon recommended against it. More effective physician-patient communication about CPM is needed to reduce potential overtreatment.
Conflict of interest statement
Figures
Comment in
-
Contralateral Prophylactic Mastectomy: Aligning Patient Preferences and Provider Recommendations.JAMA Surg. 2017 Mar 1;152(3):282-283. doi: 10.1001/jamasurg.2016.4750. JAMA Surg. 2017. PMID: 28002558 No abstract available.
Similar articles
-
Social and Clinical Determinants of Contralateral Prophylactic Mastectomy.JAMA Surg. 2014 Jun;149(6):582-9. doi: 10.1001/jamasurg.2013.5689. JAMA Surg. 2014. PMID: 24849045 Free PMC article.
-
Patient Reactions to Surgeon Recommendations About Contralateral Prophylactic Mastectomy for Treatment of Breast Cancer.JAMA Surg. 2017 Jul 1;152(7):658-664. doi: 10.1001/jamasurg.2017.0458. JAMA Surg. 2017. PMID: 28384687 Free PMC article.
-
Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer.JAMA Surg. 2018 Jan 1;153(1):29-36. doi: 10.1001/jamasurg.2017.3415. JAMA Surg. 2018. PMID: 28903158 Free PMC article.
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3 PMID: 15495033 Updated. Review.
-
Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients.Expert Rev Anticancer Ther. 2020 Mar;20(3):159-166. doi: 10.1080/14737140.2020.1732213. Epub 2020 Feb 28. Expert Rev Anticancer Ther. 2020. PMID: 32077338 Free PMC article. Review.
Cited by
-
Neuroendocrine neoplasms of the breast: a review of literature.Virchows Arch. 2024 Aug;485(2):197-212. doi: 10.1007/s00428-024-03856-y. Epub 2024 Jul 9. Virchows Arch. 2024. PMID: 38980337 Free PMC article. Review.
-
"Peace of Mind" After Mastectomy: A Scoping Review.Ann Surg Oncol. 2024 Aug;31(8):5168-5179. doi: 10.1245/s10434-024-15360-3. Epub 2024 May 8. Ann Surg Oncol. 2024. PMID: 38717543 Review.
-
ASO Author Reflections: "Peace of Mind" After Surgery for Breast Cancer: Implications for Preference-Sensitive Shared Decision Making.Ann Surg Oncol. 2024 Aug;31(8):5209-5210. doi: 10.1245/s10434-024-15408-4. Epub 2024 May 7. Ann Surg Oncol. 2024. PMID: 38713391 No abstract available.
-
Examining Race and Patient-Reported Outcomes After Contralateral Prophylactic Mastectomy with Reconstruction.Ann Surg Oncol. 2024 Feb;31(2):966-973. doi: 10.1245/s10434-023-14527-8. Epub 2023 Nov 16. Ann Surg Oncol. 2024. PMID: 37973646
-
Explaining risks and benefits of loco-regional treatments to patients.Breast. 2023 Oct;71:132-137. doi: 10.1016/j.breast.2023.08.006. Epub 2023 Aug 22. Breast. 2023. PMID: 37634470 Free PMC article.
References
-
- Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. Journal of the National Cancer Institute. 2014;106(8) - PubMed
-
- King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(16):2158–2164. - PubMed
-
- Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genetics in medicine : official journal of the American College of Medical Genetics. 2014;16(7):516–521. - PubMed
-
- Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Annals of surgical oncology. 2009;16(10):2697–2704. - PubMed
-
- Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Annals of surgical oncology. 2009;16(10):2691–2696. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
